Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Steven Vicik, PhD, as Chief Technical Officer (CTO). Dr. Steven Vicik joins the company with over 25 years of experience in pharmaceutical process and product development, manufacturing operations, as well as supply chain design and distribution for large and small molecule drugs. In his role as CTO, he will lead and execute Actym’s technology strategy and advance Actym’s proprietary platform, S. Typhimurium-Attenuated Cancer Therapy (STACT), which represents a novel approach to achieving comprehensive immunological reprogramming of the tumor microenvironment (TME). The appointment comes after Actym recently announced a Series A extension that will support a Phase 1 clinical trial designed to achieve proof of mechanism for Actym’s lead candidate, ACTM-838.
“Welcoming Steve to Actym represents a valuable addition to our expert-led management team,” said Dr. Christopher D. Thanos, President, CEO, and Co-founder of Actym. “With Steve contributing his technical expertise to our product development vision, we are well-equipped to translate our team’s deep understanding of the tumor microenvironment into furthering our novel approach for effective and safe cancer treatments.”
Commenting on his appointment, Dr. Vicik added, “Actym is developing an innovative drug modality with exciting potential to reprogram the TME. It is a great opportunity to contribute to the development process of ACTM-838 as we move toward clinical evaluation.”
SOURCE: PRNewswire